Gharib Hussam M, Abajy Mohammad Y, Omaren Abdulnaser
Department of Pharmacology, Faculty of Pharmacy, Damascus University, Syria.
Department of Biochemistry, Faculty of Pharmacy, Aleppo University, Syria.
Heliyon. 2020 Apr 24;6(4):e03812. doi: 10.1016/j.heliyon.2020.e03812. eCollection 2020 Apr.
The treatment of infections in diabetic patients by fluoroquinolone antibiotics is associated with a reduced risk of coronary artery disease, and may improve endothelium-derived hyperpolarizing factor (EDHF) efficacy. The inflammatory marker C-reactive protein (CRP) is an important predictor of cardiovascular events, and vascular endothelium dysfunction, which makes this marker a target for drug-based treatment. This study aims to investigate the relation between the treatment by fluoroquinolones with CRP plasma levels, as well as acetylecholine (ACh)-induced small conductance calcium-activated potassium channels (SK)-dependent blood pressure (BP) reduction deviations in wistar rats after inducing a type 2-like diabetes with aging state after four months of streptozotocin (STZ) injection. Experimental animals were divided into four groups, group 1: diabetic animals were treated with moxifloxacin (n = 15), group 2: diabetic animals were treated with levofloxacin (n = 15), group 3: diabetic control animals (n = 15), and group 4: non-diabetic control animals (n = 6). The levels of plasma CRP, as well as ACh-induced SK-dependent BP reduction deviations were compared four months after the development of diabetes, after that; two groups were treated with fluoroquinolones, four months after the treatment; CRP-plasma levels, as well as ACh-induced SK-dependent BP reduction deviations were also evaluated and compared for all groups. Sustained hyperglycemia after the induction of diabetes elevated CRP plasma levels, and reduced ACh-induced SK-dependent BP reduction, observed diabetes-induced variations were minimal in fluoroquinolones treated diabetic groups compared with diabetic control group, In conclusion, the treatment with fluoroquinolone antibiotics in diabetic wistars may be associated with a lowering in CRP levels progression, and improvement in SK vitality, which indicates the importance of treating infections in diabetics by fluoroquinolones to mitigate some vascular complications signs that lead to morbidity and mortality in diabetes.
用氟喹诺酮类抗生素治疗糖尿病患者的感染与降低冠状动脉疾病风险相关，并且可能改善内皮源性超极化因子（EDHF）的功效。炎症标志物C反应蛋白（CRP）是心血管事件和血管内皮功能障碍的重要预测指标，这使得该标志物成为基于药物治疗的靶点。本研究旨在探讨氟喹诺酮类药物治疗与CRP血浆水平之间的关系，以及在注射链脲佐菌素（STZ）四个月后诱导出类似2型糖尿病且伴有衰老状态的Wistar大鼠中，乙酰胆碱（ACh）诱导的小电导钙激活钾通道（SK）依赖性血压（BP）降低偏差。实验动物分为四组，第1组：用莫西沙星治疗的糖尿病动物（n = 15），第2组：用左氧氟沙星治疗的糖尿病动物（n = 15），第3组：糖尿病对照动物（n = 15），第4组：非糖尿病对照动物（n = 6）。在糖尿病发生四个月后比较血浆CRP水平以及ACh诱导的SK依赖性BP降低偏差，之后；两组用氟喹诺酮类药物治疗，治疗四个月后；还对所有组的CRP血浆水平以及ACh诱导的SK依赖性BP降低偏差进行了评估和比较。糖尿病诱导后持续的高血糖会升高CRP血浆水平，并降低ACh诱导的SK依赖性BP降低，与糖尿病对照组相比，在氟喹诺酮类药物治疗的糖尿病组中观察到的糖尿病诱导变化最小。总之，用氟喹诺酮类抗生素治疗糖尿病Wistar大鼠可能与CRP水平进展降低以及SK活力改善有关，这表明用氟喹诺酮类药物治疗糖尿病感染对于减轻一些导致糖尿病发病和死亡的血管并发症迹象具有重要意义。
